Oncogenic role of eIF-5A2 in the development of ovarian cancer

Cancer Res. 2004 Jun 15;64(12):4197-200. doi: 10.1158/0008-5472.CAN-03-3747.

Abstract

Amplification of 3q26 is one of the most frequent chromosomal alterations in many solid tumors, including ovarian, lung, esophageal, prostate, breast, and nasopharyngeal cancers. A candidate oncogene to eukaryotic initiation factor 5A2 (eIF-5A2), a member of eukaryotic initiation factor 5A subfamily, has been isolated from a frequently amplified region at 3q26.2. In this work, the tumorigenic ability of eIF-5A2 was demonstrated by anchorage-independent growth in soft agar and tumor formation in nude mice. Furthermore, antisense DNA against eIF-5A2 could inhibit cell growth in ovarian cancer cell line UACC-1598 with amplification of eIF-5A2 in form of double minutes. Cell growth rate in UACC-1598 was also inhibited when the expression level of EIF-5A2 was decreased by the reduction of the copy number of double minutes. The correlation of EIF-5A2 overexpression and clinical features of ovarian cancer was investigated using tissue microarray, and the result showed that eIF-5A2 overexpression was significantly associated with the advanced stage of ovarian cancer. These findings suggest that eIF-5A2 plays important roles in ovarian pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Division / genetics
  • Cell Line, Tumor
  • Chromosome Mapping
  • DNA, Antisense / genetics
  • Female
  • Humans
  • Mice
  • NIH 3T3 Cells
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Peptide Initiation Factors / antagonists & inhibitors
  • Peptide Initiation Factors / biosynthesis
  • Peptide Initiation Factors / genetics*
  • Signal Transduction / genetics

Substances

  • DNA, Antisense
  • Peptide Initiation Factors
  • eIF-5A2